Effect of branched-chain amino acid-enriched nutritional supplementation on interferon therapy in Japanese patients with chronic hepatitis C virus infection: a retrospective study

Virology Journal

Michio Sata²  Tatsuya Ide²  Takumi Kawaguchi²  Yumiko Nagao¹ 

[1] Department of Digestive Disease Information & Research, Kurume University School of Medicine, Kurume, Fukuoka, 830-0011, Japan;Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Kurume, Fukuoka, 830-0011, Japan

关键词: Low-dose long-term IFN therapy;    Standard IFN therapy;    Hepatitis C virus (HCV);    Interferon (IFN);    Branched-chain amino acids (BCAA);   

Others  :  1153083
DOI  :  10.1186/1743-422X-9-282

 received in 2012-07-26, accepted in 2012-11-05,  发布年份 2012

【 摘 要 】

Background

The aims of this study were to evaluate the effects of nutritional supplementation with branched-chain amino acids (BCAA) with zinc component (Aminofeel®) on adherence to and outcome of therapy in patients treated with interferon (IFN) for chronic hepatitis C and cirrhosis and to determine whether to recommend the supplement.

Methods

In this retrospective study, 51 patients who received IFN therapy were investigated among 203 consecutive patients who visited our hospital and were advised regarding the potential benefit of taking Aminofeel®. Each patient was free to choose whether to purchase and take Aminofeel®.

Results

Twenty four patients (group 1-A) took Aminofeel® during standard IFN therapy and 13 (group 1-B) did not. Low-dose, long-term IFN (maintenance) therapy, mainly peglated (Peg)-IFN alpha 2a, was administered to 14 patients who were difficult to treat, because of no effect or harmful side effects with standard IFN therapy, and who had advanced liver fibrosis. Among the 14, 11 patients (group 2-A) took Aminofeel® and 3 (group 2-B) did not. The prevalence of obesity was significantly higher (P=0.04) in group 1-A than in group 1-B. The rate of adherence to IFN therapy was higher in group 1-A (83.3%) than in group 1-B (53.8%, P=0.05). There were no significant differences between the two groups in the rates of sustained virological response (SVR) to IFN therapy. According to multivariate analysis, two factors, SVR and intake of Aminofeel®, were associated with successful adherence to IFN therapy. The adjusted odds ratios for these two factors were 13.25 and 12.59, respectively, and each was statistically significant. The SVR rate of maintenance IFN therapy was in 18.2% group 2-A and 0% in group 2-B.

Conclusion

Our data show that BCAA intake is useful for adherence to and effect of IFN therapy for patients with chronic hepatitis C. Nutritional supplementation with BCAA seems to be useful for HCV-infected patients receiving IFN therapy because it is impossible to introduce standard treatment for all patients among Japan's aging population.

【 授权许可】

   
2012 Nagao et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Kiyosawa K, Uemura T, Ichijo T, Matsumoto A, Yoshizawa K, Gad A, Tanaka E: Hepatocellular carcinoma: recent trends in Japan. Gastroenterology 2004, 127(Suppl 1):17-26.
• [2]Asahina Y, Tsuchiya K, Tamaki N, Hirayama I, Tanaka T, Sato M, Yasui Y, Hosokawa T, Ueda K, Kuzuya T, Nakanishi H, Itakura J, Takahashi Y, Kurosaki M, Enomoto N, Izumi N: Effect of aging on risk for hepatocellular carcinoma in chronic hepatitis C virus infection. Hepatology 2010, 52:518-527.
• [3]Yoshida H, Shiratori Y, Moriyama M, Arakawa Y, Ide T, Sata M, Inoue O, Yano M, Tanaka M, Fujiyama S, Nishiguchi S, Kuroki T, Imazeki F, Yokosuka O, Kinoyama S, Yamada G, Omata M: Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT study group. Inhibition of hepatocarcinogenesis by interferon therapy. Ann Intern Med 1999, 131:174-181.
• [4]Yoshida H, Arakawa Y, Sata M, Nishiguchi S, Yano M, Fujiyama S, Yamada G, Yokosuka O, Shiratori Y, Omata M: Interferon therapy prolonged life expectancy among chronic hepatitis C patients. Gastroenterology 2002, 123:483-491.
• [5]Lok AS, Everhart JE, Wright EC, Di Bisceglie AM, Kim HY, Sterling RK, Everson GT, Lindsay KL, Lee WM, Bonkovsky HL, Dienstag JL, Ghany MG, Morishima C, Morgan TR, HALT-C Trial Group: Maintenance peginterferon therapy and other factors associated with hepatocellular carcinoma in patients with advanced hepatitis C. Gastroenterology 2011, 140:840-849.
• [6]Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK: Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001, 358:958-965.
• [7]Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gonçales FL Jr, Häussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J: Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002, 347:975-982.
• [8]Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, Marcellin P, Ramadori G, Bodenheimer H Jr, Bernstein D, Rizzetto M, Zeuzem S, Pockros PJ, Lin A, Ackrill AM, PEGASYS International Study Group: Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004, 140:346-355.
• [9]Fried MW: Side effects of therapy of hepatitis C and their management. Hepatology 2002, 36(Suppl 1):237-244.
• [10]Russo MW, Fried MW: Side effects of therapy for chronic hepatitis C. Gastroenterology 2003, 124:1711-1719.
• [11]Muto Y, Sato S, Watanabe A, Moriwaki H, Suzuki K, Kato A, Kato M, Nakamura T, Higuchi K, Nishiguchi S, Kumada H, Long-Term Survival Study Group: Effects of oral branchedchain amino acid granules on event-free survival in patients with liver cirrhosis. Clin Gastroenterol Hepatol 2005, 3:705-713.
• [12]Marchesini G, Zoli M, Dondi C, Bianchi G, Cirulli M, Pisi E: Anticatabolic effect of branched-chain amino acid-enriched solutions in patients with liver cirrhosis. Hepatology 1982, 2:420-425.
• [13]Honda M, Honda M, Takehana K, Sakai A, Tagata Y, Shirasaki T, Nishitani S, Muramatsu T, Yamashita T, Nakamoto Y, Mizukoshi E, Sakai Y, Yamashita T, Nakamura M, Shimakami T, Yi M, Lemon SM, Suzuki T, Wakita T, Kaneko S, Hokuriku Liver Study Group: Malnutrition impairs interferon signaling through mTOR and FoxO pathways in patients with chronic hepatitis C. Gastroenterology 2011, 141:128-140.
• [14]Kawaguchi T, Nagao Y, Matsuoka H, Ide T, Sata M: Branched-chain amino acid-enriched supplementation improves insulin resistance in patients with chronic liver disease. Int J Mol Med 2008, 22:105-112.
• [15]Kawaguchi T, Taniguchi E, Itou M, Sumie S, Oriishi T, Matsuoka H, Nagao Y, Sata M: Branched-chain amino acids improve insulin resistance in patients with hepatitis C virus-related liver disease: report of two cases. Liver Int 2007, 27:1287-1292.
• [16]Nagao Y, Matsuoka H, Kawaguchi T, Sata M: Aminofeel® improves the sensitivity to taste in patients with HCV-infected liver disease. Med Sci Monit 2010, 16:7-12.
• [17]Nagao Y, Kawaguchi T, Kakuma T, Ide T, Sata M: Post-marketing surveillance study for efficacy and safety of Aminofeel®, a branched chain amino acid-enriched supplement including zinc. J New Rem & Clin 2011, 60:1046-1063. in Japanese
• [18]Wilkinson DJ, Smeeton NJ, Watt PW: Ammonia metabolism, the brain and fatigue; revisiting the link. Prog Neurobiol 2010, 91:200-219.
• [19]Huang A, Fuchs D, Widner B, Glover C, Henderson DC, Allen-Mersh TG: Serum tryptophan decrease correlates with immune activation and impaired quality of life in colorectal cancer. Br J Cancer 2002, 86:1691-1696.
• [20]Yamamoto M, Iwasa M, Matsumura K, Nakagawa Y, Fujita N, Kobayashi Y, Kaito M, Takeda K, Adachi Y: Improvement of regional cerebral blood flow after oral intake of branched-chain amino acids in patients with cirrhosis. World J Gastroenterol 2005, 11:6792-6799.
• [21]Kawaguchi T, Izumi N, Charlton MR, Sata M: Branched-chain amino acids as pharmacological nutrients in chronic liver disease. Hepatology 2011, 54:1063-1070.
• [22]Sasaki M, Sara M, Ishibashi M, Uchimura N, Tanikawa K: Decreased regional cerebral blood flow during interferon therapy. Hepatol Res 1997, 9:1-8.
• [23]Nagao Y, Sata M: Serum albumin and mortality risk in a hyperendemic area of HCV infection in Japan. Virol J 2010, 7:375. BioMed Central Full Text
• [24]Takano S, Ito Y, Yokosuka O, Ohto M, Uchiumi K, Hirota K, Omata M: A multicenter randomized controlled dose study of ursodeoxycholic acid for chronic hepatitis C. Hepatology 1994, 20:558-564.
• [25]Arase Y, Ikeda K, Murashima N, Chayama K, Tsubota A, Koida I, Suzuki Y, Saitoh S, Kobayashi M, Kumada H: The long term efficacy of glycyrrhizin in chronic hepatitis C patients. Cancer 1997, 79:1494-1500.
• [26]van Rossum TG, Vulto AG, Hop WC, Brouwer JT, Niesters HG, Schalm SW: Intravenous glycyrrhizin for the treatment of chronic hepatitis C: a double-blind, randomized, placebo-controlled phase I/II trial. J Gastroenterol Hepatol 1999, 14:1093-1099.
• [27]Murashima S, Tanaka M, Haramaki M, Yutani S, Nakashima Y, Harada K, Ide T, Kumashiro T, Sata M: A decrease in AFP level related to administration of interferon in patients with chronic hepatitis C and a high level of AFP. Dig Dis Sci 2006, 51:808-812.
• [28]Nomura H, Kashiwagi Y, Hirano R, Tanimoto H, Tsutsumi N, Higashi M, Ishibashi H: Efficacy of low dose long-term interferon monotherapy in aged patients with chronic hepatitis C genotype 1 and its relation to alpha-fetoprotein: A pilot study. Hepatol Res 2007, 37:490-497.
• [29]Kawaguchi T, Sumie S, Itou M, Taniguchi E, Matoba T, Sata M: Clinical benefits and cost-effectiveness of 17-year treatment with low-dose interferon-alpha 2b in a patient with chronic hepatitis C: a case report. Dig Dis Sci 2009, 54:690-694.
• [30]Shima C, Yamada A, Tsubosaka M, Sakurai M, Nakatani K, Kinoshita K, Kishida O, Fujimoto T, Minami Y: A case of chronic hepatitis C with sustained virological response by an intermittent use of low dose pegylated interferon. Kanzo 2008, 49:470-475. in Japanese
• [31]Nagao Y, Sata M: Insulin resistance and lichen planus in patients with HCV-infectious liver diseases. J Gastroenterol Hepatol 2008, 23:580-585.
• [32]Lee SC, Antony A, Lee N, Leibow J, Yang JQ, Soviero S, Gutekunst K, Rosenstraus M: Improved version 2.0 qualitative and quantitative AMPLICOR reverse transcription-PCR tests for hepatitis C virus RNA: calibration to international units, enhanced genotype reactivity, and performance characteristics. J Clin Microbiol 2000, 38:4171-4179.
• [33]Sizmann D, Boeck C, Boelter J, Fischer D, Miethke M, Nicolaus S, Zadak M, Babiel R: Fully automated quantification of hepatitis C virus (HCV) RNA in human plasma and human serum by the COBAS AmpliPrep/COBAS TaqMan system. J Clin Virol 2007, 38:326-333.
• [34]Dusheiko G, Schmilovitz-Weiss H, Brown D, McOmish F, Yap PL, Sherlock S, McIntyre N, Simmonds P: Hepatitis C virus genotypes: an investigation of type-specific differences in geographic origin and disease. Hepatology 1994, 19:13-18.
• [35]Guide ADAR: Blood glucose monitors and data management. Diabetes Forecast 2003, 2003(56):77-79.
• [36]The sixth report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure Arch Intern Med 1997, 157:2413-2446.